Logo
x

Search

Subscribe Now

non-alcoholic steatohepatitis

Novartis & Pfizer Enter into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH)

Novartis & Pfizer Enter into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH)

  • October 29, 2018
Pfizer’s Ervogastat + Clesacostat Receives the US FDA’s Fast Track Designation for the Treatment of Non-Alcoholic Steatohepatitis

    Pfizer’s Ervogastat + Clesacostat Receives the US FDA’s Fast Track Designation for the Treatment of Non-Alcoholic Steatohepatitis

    • May 27, 2022
    Madrigal Reports Results of Resmetirom in P-III (MAESTRO-NAFLD-1) Study for the Treatment of Non-Alcoholic Steatohepatitis

      Madrigal Reports Results of Resmetirom in P-III (MAESTRO-NAFLD-1) Study for the Treatment of Non-Alcoholic Steatohepatitis

      • February 1, 2022
      Madrigal Provides Update in the P-III (MAESTRO-NAFLD-1) Trial of Resmetirom for the Treatment of Non-Alcoholic Steatohepatitis

        Madrigal Provides Update in the P-III (MAESTRO-NAFLD-1) Trial of Resmetirom for the Treatment of Non-Alcoholic Steatohepatitis

        • December 31, 2021
        Novartis & Pfizer Enter into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH)

          Novartis & Pfizer Enter into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH)

          • October 29, 2018
          Image

          Incisive News in 3 Shots.

          Contact Us

          Our Information

          Follow Us

          Copyright © 2025 PharmaShots - All Rights Reserved.